Compare VRCA & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | DLNG |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 142.3M |
| IPO Year | 2018 | N/A |
| Metric | VRCA | DLNG |
|---|---|---|
| Price | $5.85 | $3.53 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 29.4K | 29.0K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | N/A | ★ 5.18% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $94.44 | $1.10 |
| P/E Ratio | ★ N/A | $3.04 |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.52 | $3.40 |
| 52 Week High | $9.82 | $4.45 |
| Indicator | VRCA | DLNG |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 29.50 |
| Support Level | $5.32 | $3.45 |
| Resistance Level | $6.48 | $3.86 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 8.33 | 3.78 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.